HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--May 5, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX - News) is pleased to announce today that the Company's saliva-based version of its NicAlert(TM) product for testing for tobacco use or exposure has now achieved certification in Europe with the CE Mark. The CE Mark indicates that the product complies with EU safety, environmental, and quality standards and makes the product eligible for sale in the European Union.
